Adma Biologics, Inc. ADMA
We are a U.S. based end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. 10-K, Item 1
- Headquarters
- Ramsey, NJ
- CEO
- Adam S. Grossman
- Next results
- around Jan 11, 2027
Where each dollar of revenue went, FY2025
Revenue of $510.2M through the costs to a net profit of $146.9M · income statement of the 10-K
ADMA among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
10 new risk paragraphs and 4 accounting facts worth reading about. 10-K filed Feb 25, 2026 against Mar 18, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
4facts worth reading about the other 7 checks found nothing to note
-
Receivables growing faster than revenueReceivables +216.9% ($50.0M to $158.4M) vs revenue +19.6% ($426.5M to $510.2M), +197.2 pts apart
-
Cash from operations lower than net incomeCash from operations $50.4M vs net income $146.9M (FY ending Dec 31, 2025)
-
Late filing notice (NT 10-K or NT 10-Q)NT 10-K filed Mar 3, 2025: the company said its 10-K would be late
-
Critical audit matters changedNew this year: Sufficiency of audit evidence over inventory (“As disclosed in Notes 2 and 3 to the consolidated financial statements, the Company held $206.4 million of inventory as of December 31, 2025. Inventories are comprised of raw materials, work-in-process, and finished goods.”). No longer listed: Valuation of the U.S. Medicaid rebate accrual for immunoglobulin products
-
Inventory +21.3% ($170.2M to $206.5M) vs revenue +19.6% ($426.5M to $510.2M), +1.7 pts apart
6 more checks with nothing to note
-
Same auditor in both 10-Ks: KPMG LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
10 paragraphs in Risk Factors that were not in the 10-K filed Mar 18, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Mar 18, 2025 10-K, ITEM 1A
Issues in the development and use of AI may result in reputational harm and increased liability exposure.
-
Item 1A · new paragraph · not in the 10-K filed Mar 18, 2025 10-K, ITEM 1A
Our business may be adversely affected by a pandemic, epidemic, or outbreak of an unknown or emerging infections disease.
-
Item 1A · new paragraph · not in the 10-K filed Mar 18, 2025 10-K, ITEM 1A
Regulatory authorities may not accept data from foreign clinical studies or sites or may find that such data is not sufficiently representative of the population of the approving jurisdiction;
-
Item 1A · new paragraph · not in the 10-K filed Mar 18, 2025 10-K, ITEM 1A
On August 5, 2025 (the “JPM Closing Date”), we entered into a credit agreement with JPMorgan and certain other lenders party thereto (the “JPM Credit Agreement”) (see “Liquidity and Capital Resources”). The JPM Credit Agreement provides for a total of $300 million in senior secured credit facilities (the “JPM Credit Facilities”)…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $154.1M | $258.2M | $426.5M | $510.2M |
| Net income | −$65.9M | −$28.2M | $197.7M | $146.9M |
| Operating cash flow | −$59.5M | $8.8M | $118.7M | $50.4M |
| Free cash flow | −$73.4M | $4.0M | $110.4M | $27.8M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$510.2M ▲ 19.6% in FY2025$146.9M ▼ 25.7% in FY2025$27.8M ▼ 74.8% in FY2025
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 5, 2026Grossman Adam S. (Director, Officer) gave notice of a planned sale of 189,000 shares worth about $2.0M Form 144, approximate sale date Nov 5, 2026, under a 10b5-1 plan adopted Nov 14, 2025
-
8-KNov 4, 2026Quarterly results 8-K item 2.02
-
10-QNov 4, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Adma Biologics, Inc., Ramsey, NJ · from the 10-K filed Feb 25, 2026
We are a U.S. based end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.
- Headquarters
- Ramsey, NJ
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Mar 18, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ADMA/export.csv") into a cell.